ADC Therapeutics SA Files Definitive Proxy Statement

Ticker: ADCT · Form: DEF 14A · Filed: Apr 21, 2025 · CIK: 1771910

Adc Therapeutics SA DEF 14A Filing Summary
FieldDetail
CompanyAdc Therapeutics SA (ADCT)
Form TypeDEF 14A
Filed DateApr 21, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: proxy-statement, governance, annual-meeting

TL;DR

ADC Therapeutics SA proxy filing is out for June 3rd meeting. Vote on directors & pay.

AI Summary

ADC Therapeutics SA filed a definitive proxy statement (DEF 14A) on April 21, 2025, for its annual meeting on June 3, 2025. The filing outlines the company's governance and proposals to be voted on by shareholders, including the election of directors and executive compensation.

Why It Matters

This filing provides shareholders with crucial information regarding company leadership and executive compensation, enabling informed voting decisions at the upcoming annual meeting.

Risk Assessment

Risk Level: low — This is a routine proxy filing detailing corporate governance and shareholder voting matters, not indicating new financial risks.

Key Players & Entities

  • ADC Therapeutics SA (company) — Registrant
  • 0001140361-25-014654 (filing_id) — Accession Number
  • 20250421 (date) — Filing Date
  • 20250603 (date) — Period of Report / Meeting Date

FAQ

What is the purpose of this DEF 14A filing?

The purpose of this DEF 14A filing is to provide shareholders with a definitive proxy statement for the company's annual meeting, detailing information for voting on matters such as director elections and executive compensation.

When is the period of report for this filing?

The period of report for this filing is June 3, 2025.

Who is the filer of this document?

The filer of this document is ADC Therapeutics SA.

What is the standard industrial classification for ADC Therapeutics SA?

The standard industrial classification for ADC Therapeutics SA is Pharmaceutical Preparations [2834].

What is the business address of ADC Therapeutics SA?

The business address of ADC Therapeutics SA is Biopole, Route de la Corniche 3B, Epalinges, V8, 1066.

Filing Details

This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 21, 2025 regarding ADC Therapeutics SA (ADCT).

View full filing on EDGAR

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.